Lauren V. Wood

Last updated
Lauren V. Wood
Wood NCI.jpg
Alma mater


Scientific career
Fields
  • Therapeutic Vaccines
  • HPV
  • Hepatitis C
  • HIV
Institutions

Lauren V. Wood is an American allergist, immunologist, and staff physician [1] at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. [2] She is known for conducting studies of vaccines for cancer, [3] Human papillomavirus (HPV), Hepatitis C, and HIV [4] especially for use with children, teens and young adults. [5] She holds the rank of captain in the U.S. Public Health Service (PHS).

Contents

Education

Wood earned a B.A. degree in biology from Oberlin College and in 1984 received her M.D. degree from Duke University School of Medicine. [1] [6] She completed a combined residency in internal medicine and pediatrics at Baylor College of Medicine Affiliated Hospitals in Houston, Texas. [1] She became board certified in both specialties. [1]

Career

Wood's clinical research interests include therapeutic vaccines and immune-based therapies for cancer and HIV infection, as well as research on other chronic viral infections such as (HPV) and hepatitis C. [7] She also conducts investigations of HIV and HPV transmission and associated risk behaviors.

Wood was awarded a fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) and spent two years in the laboratory of now NIAID-director Anthony S. Fauci, M.D., where she conducted investigations of HIV-specific cellular and humoral immune responses. She then worked for a year with NIAID's Henry Masur, M.D. and H. Clifford Lane, M.D. in that Institute's HIV/AIDS Clinical Research Program.

Lauren Wood was the keynote speaker for the event, "Meet the Faces of Clinical Research: Beyond Inclusion," co-sponsored by NIH's Office of Research on Women's Health and FDA's Office on Women's Health. May 14, 2015 Wood NIH Record.jpg
Lauren Wood was the keynote speaker for the event, “Meet the Faces of Clinical Research: Beyond Inclusion,” co-sponsored by NIH's Office of Research on Women's Health and FDA's Office on Women's Health. May 14, 2015

In 1992, she was recruited to the NCI by Philip A. Pizzo, M.D. She served as a senior staff member of the NCI Pediatric HIV Working Group, first under Pizzo and subsequently under Robert Yarchoan, M.D. In 1994, she was promoted to Senior Surgeon. [8] At NCI, her clinical research focused on the investigation of antiretroviral agents and immune-based therapies in HIV-infected children, adolescents, and young adults, including the initial studies of lamivudine (3TC) and ritonavir that led to FDA approval for use in children. Wood also conducted studies of recombinant IL-2, HIV therapeutic vaccines and adherence to antiretroviral treatment. With other NCI colleagues, Wood also conducted investigations of the infectious, malignant, and psychosocial complications of pediatric HIV disease. [6] In 2005, Wood joined the newly formed the Vaccine Branch at NCI and was charged with developing a clinical translational research program, which she now heads.

At the NCI, she is responsible for the bench-to-bedside clinical translation and implementation of in-human studies investigating novel vaccine platforms and immune-based therapies for cancer and HIV infection. [6] [9]

Wood's research extends to investigations of the TCRγ-alternative reading frame protein (TARP) peptide cancer vaccine in prostate cancer patients with PSA biochemical recurrence, a form of immunotherapy discovered by NCI veteran investigator Dr. Ira Pastan. A novel and potentially promising is the TARP is found in more than 90 percent of prostate cancers and about 50 percent of breast cancers. [10] Her work and research has been published in the Annals of Internal Medicine , [11] The Pediatric Infectious Disease Journal , [12] AIDS and Behavior , [13] The Archives of Dermatology , [14] The Journal of Clinical Microbiology , [15] The Expert Review of Vaccines , [16] Seminars in Oncology, [17] The American Journal of Roentgenology , [18] Blood , [19] The Journal of Immunology , [20] AIDS Patient Care and STDs, [21] The Journal of Acquired Immune Deficiency Syndromes , [22] Mitochondrion, [23] The Annals of the New York Academy of Sciences , [24] AIDS Care, [25] The Journal of Translational Medicine , [26] Molecular Therapy, [27] and others. In addition to publishing in peer-reviewed journals, she has also served as a reviewer for the Journal of Pediatrics and as an associate editor for Clinical and Diagnostic Laboratory Immunology. [8]

Honors

In addition to authoring numerous scientific publications and presenting her research at national and international scientific meetings, Wood has served on multiple FDA, White House, and other interagency advisory, review and data safety monitoring committees. [8] She is assistant professor at the Uniformed Services University of the Health Sciences (USUHS). She is a member of the board of directors of the NIH Children's Inn. [28] [29]

Related Research Articles

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

<span class="mw-page-title-main">Didanosine</span> Chemical compound

Didanosine, sold under the brand name Videx, is a medication used to treat HIV/AIDS. It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

<span class="mw-page-title-main">Wistar Institute</span> American biomedical research institute

The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

Infection with HIV, a retrovirus, can be managed with treatment but without treatment can lead to a spectrum of conditions including AIDS.

Long-term nonprogressors (LTNPs), sometimes also called elite controllers, are individuals infected with HIV, who maintain a CD4 count greater than 500 without antiretroviral therapy with a detectable viral load. Many of these patients have been HIV positive for 30 years without progressing to the point of needing to take medication in order not to develop AIDS. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to the development of immune therapies or a therapeutic vaccine. The classification "Long-term non-progressor" is not permanent, because some patients in this category have gone on to develop AIDS.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

The co-epidemic of tuberculosis (TB) and human immunodeficiency virus (HIV) is one of the major global health challenges in the present time. The World Health Organization (WHO) reports 9.2 million new cases of TB in 2006 of whom 7.7% were HIV-infected. Tuberculosis is the most common contagious infection in HIV-Immunocompromised patients leading to death. These diseases act in combination as HIV drives a decline in immunity while tuberculosis progresses due to defective immune status. This condition becomes more severe in case of multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difficult to treat and contribute to increased mortality. Tuberculosis can occur at any stage of HIV infection. The risk and severity of tuberculosis increases soon after infection with HIV. A study on gold miners of South Africa revealed that the risk of TB was doubled during the first year after HIV seroconversion. Although tuberculosis can be a relatively early manifestation of HIV infection, it is important to note that the risk of tuberculosis progresses as the CD4 cell count decreases along with the progression of HIV infection. The risk of TB generally remains high in HIV-infected patients, remaining above the background risk of the general population even with effective immune reconstitution and high CD4 cell counts with antiretroviral therapy.

Vaccinia immune globulin (VIG) is made from the pooled blood of individuals who have been inoculated with the smallpox vaccine. The antibodies these individuals developed in response to the smallpox vaccine are removed and purified. This results in VIG. It can be administered intravenously. It is used to treat individuals who have developed progressive vaccinia after smallpox vaccination.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

Julianna Lisziewicz is a Hungarian immunologist. Lisziewicz headed many research teams that have discovered and produced immunotheraputic drugs to treat diseases like cancer and chronic infections like HIV/AIDS. Some of these drugs have been successfully used in clinical trials.

<span class="mw-page-title-main">Nadia Dowshen</span> American pediatrician

Nadia Lauren Dowshen is an American pediatrician and adolescent medicine physician. She specializes in the care of youth living with HIV infection and medical care to transgender and gender-diverse youth. Dowshen researches health inequality, access to care, and promoting resilience in LGBT youth. As an associate professor at the Perelman School of Medicine at the University of Pennsylvania, she is also the medical director and co-founder of the Gender and Sexuality Development Clinic.

Crystal C. Watkins Johansson is an American neuroscientist and psychiatrist and associate professor of neuroscience at Johns Hopkins University School of Medicine as well as the director of the Sheppard Pratt Memory Clinic in Neuropsychiatry in Baltimore, Maryland. Johansson was the first Black female Meyerhoff Scholar to obtain an MD/PhD from the University of Maryland, Baltimore County. During her MD/PhD she developed a novel treatment for gastrointestinal in patients with diabetes that led to a patent for a pharmacological compound in 2000. Johansson is a practicing neuropsychiatrist with a focus on geriatric psychiatry and she conducts brain imaging research as well as research on cancer in African American women.

<span class="mw-page-title-main">Andrew Kambugu</span> Ugandan physician

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute and a Honorary Senior lecturer at Makerere University College of Sciences. He is also an Adjunct Associate Professor at the University of Minnesota. In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.

<span class="mw-page-title-main">Nirali N. Shah</span> American physician-scientist and pediatric hematologist-oncologist

Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.

<span class="mw-page-title-main">Judith Aberg</span> American physician

Judith Aberg is an American physician who is the George Baehr Professor of Clinical Medicine at Mount Sinai Hospital. She was appointed Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai. Her research considered infectious diseases, including HIV/AIDS and COVID-19.

References

  1. 1 2 3 4 "Lauren V. Wood, M.D." (PDF). Ccr.cancer.gov. 2014-08-12. Retrieved 2015-11-17.
  2. ↑ Jackson, Cynthia L.; Nunn, Eleanor (2003). Historically Black Colleges and Universities: A Reference Handbook. ABC-CLIO, Inc. p. 47. ISBN   978-1851094226.
  3. ↑ Garnett, Carla (2013-02-15). "For MLK Program, Wood Conveys 'Passion for Science of Treating Patients' – The NIH Record –". Nihrecord.nih.gov. Retrieved 2015-11-17.
  4. ↑ James, Thomas (26 January 2015). "NIH Clinical Trial Aims to Stop Aggressive Tumors". WUSA. Retrieved 18 November 2015.
  5. ↑ "NCI Visuals Online: Image Details". visualsonline.cancer.gov. Retrieved 2015-11-19.
  6. 1 2 3 "2004 Biomedical Science Careers Student Conference" (PDF). Bscp.org. Archived from the original (PDF) on 2015-09-23. Retrieved 2015-11-17.
  7. ↑ "Lauren V. Wood, MD". Demystifying Medicine. NIH. Retrieved 18 November 2015.
  8. 1 2 3 "Adolescents and AIDS: Millennium Milestones". NIH Clinical Center Archive. 2000. Retrieved 18 November 2015.
  9. ↑ "Inside NCI: A Conversation with Dr. Lauren Wood about Cancer" . Retrieved 18 November 2015.
  10. ↑ Garnett, Carla (2013-02-15). "For MLK Program, Wood Conveys 'Passion for Science of Treating Patients' – The NIH Record – February 15, 2013". Nihrecord.nih.gov. Retrieved 2015-11-17.
  11. ↑ Miller, Kirk D.; Cameron, Miriam; Wood, Lauren V.; Dalakas, Marinos C.; Kovacs, Joseph A. (2000-08-01). "Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases". Annals of Internal Medicine. 133 (3): 192–196. doi: 10.7326/0003-4819-133-3-200008010-00010 . ISSN   0003-4819. PMID   10906833.
  12. ↑ Martin, Staci; Elliott-DeSorbo, Deborah K.; Wolters, Pamela L.; Toledo-Tamula, Mary Anne; Roby, Gregg; Zeichner, Steve; Wood, Lauren V. (2007). "Patient, Caregiver and Regimen Characteristics Associated With Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Children and Adolescents". The Pediatric Infectious Disease Journal. 26 (1): 61–67. doi:10.1097/01.inf.0000250625.80340.48. PMID   17195708. S2CID   148932.
  13. ↑ Wiener, Lori S.; Battles, Haven B.; Wood, Lauren V. (2006-09-21). "A Longitudinal Study of Adolescents with Perinatally or Transfusion Acquired HIV Infection: Sexual Knowledge, Risk Reduction Self-efficacy and Sexual Behavior". AIDS and Behavior. 11 (3): 471–478. doi:10.1007/s10461-006-9162-y. ISSN   1090-7165. PMC   2408713 . PMID   17028994.
  14. ↑ Toro, Jorge R.; Wood, Lauren V.; Patel, Nitin K.; Turner, Maria L. (2000-08-01). "Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1". Archives of Dermatology. 136 (8): 983–985. doi: 10.1001/archderm.136.8.983 . ISSN   0003-987X. PMID   10926733.
  15. ↑ Bodaghi, Sohrab; Wood, Lauren V.; Roby, Gregg; Ryder, Celia; Steinberg, Seth M.; Zheng, Zhi-Ming (2005-11-01). "Could Human Papillomaviruses Be Spread through Blood?". Journal of Clinical Microbiology. 43 (11): 5428–5434. doi:10.1128/JCM.43.11.5428-5434.2005. ISSN   0095-1137. PMC   1287818 . PMID   16272465.
  16. ↑ Arlen, Philip M.; Wood, Lauren V. (2012-01-01). "Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge™ era". Expert Review of Vaccines. 11 (3): 287–302. doi:10.1586/erv.11.183. ISSN   1476-0584. PMID   22380822. S2CID   21408417.
  17. ↑ Berzofsky, Jay A.; Terabe, Masaki; Wood, Lauren V. (2012). "Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer". Seminars in Oncology. 39 (3): 348–357. doi:10.1053/j.seminoncol.2012.02.002. PMC   3356566 . PMID   22595057.
  18. ↑ Patsalides, Athos D.; Wood, Lauren V.; Atac, Gokce K.; Sandifer, Eileen; Butman, John A.; Patronas, Nicholas J. (2002-10-01). "Cerebrovascular Disease in HIV-Infected Pediatric Patients: Neuroimaging Findings". American Journal of Roentgenology. 179 (4): 999–1003. doi:10.2214/ajr.179.4.1790999. ISSN   0361-803X. PMID   12239054.
  19. ↑ Fry, Terry J.; Connick, Elizabeth; Falloon, Judith; Lederman, Michael M.; Liewehr, David J.; Spritzler, John; Steinberg, Seth M.; Wood, Lauren V.; Yarchoan, Robert (2001-05-15). "A potential role for interleukin-7 in T-cell homeostasis". Blood. 97 (10): 2983–2990. doi: 10.1182/blood.V97.10.2983 . ISSN   0006-4971. PMID   11342421. S2CID   9325365.
  20. ↑ Wang, Jing; Shirota, Yuko; Bayik, Defne; Shirota, Hidekazu; Tross, Debra; Gulley, James L.; Wood, Lauren V.; Berzofsky, Jay A.; Klinman, Dennis M. (2015-05-01). "Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells". The Journal of Immunology. 194 (9): 4215–4221. doi:10.4049/jimmunol.1402004. ISSN   0022-1767. PMC   4402268 . PMID   25825448.
  21. ↑ Wiener, Lori; Riekert, Kristin; Ryder, Celia; Wood, Lauren V. (2004-09-01). "Assessing Medication Adherence in Adolescents with HIV When Electronic Monitoring Is Not Feasible". AIDS Patient Care and STDs. 18 (9): 527–538. doi:10.1089/apc.2004.18.527. ISSN   1087-2914. PMID   15630773.
  22. ↑ Martin, Staci; Wolters, Pamela L; Calabrese, Sarah K; Toledo-Tamula, Mary Anne; Wood, Lauren V; Roby, Gregg; Elliott-DeSorbo, Deborah K (2007). "The Antiretroviral Regimen Complexity Index". Journal of Acquired Immune Deficiency Syndromes. 45 (5): 535–544. doi: 10.1097/qai.0b013e31811ed1f1 . PMID   17589371. S2CID   19356846.
  23. ↑ Mukhopadhyay, Abhijit; Wei, Baoxian; Zullo, Steven J.; Wood, Lauren V.; Weiner, Henry (2002-10-01). "In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome". Mitochondrion. 1 (6): 511–518. doi:10.1016/S1567-7249(02)00042-9. PMID   16120303.
  24. ↑ Gonzalez, Corina E.; Samakoses, Rudi; Boler, Anne Marie; Hill, Suvimol; Wood, Lauren V. (2000-11-01). "Lymphoid Interstitial Pneumonitis in Pediatric AIDS: Natural History of the Disease". Annals of the New York Academy of Sciences. 918 (1): 358–361. doi:10.1111/j.1749-6632.2000.tb05506.x. ISSN   1749-6632. PMID   11131724. S2CID   37750346.
  25. ↑ Calabrese, Sarah K.; Martin, Staci; Wolters, Pamela L.; Toledo-Tamula, Mary A.; Brennan, Tara L.; Wood, Lauren V. (2012-09-01). "Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents". AIDS Care. 24 (9): 1092–1096. doi:10.1080/09540121.2012.699670. ISSN   0954-0121. PMC   3428222 . PMID   22799616.
  26. ↑ Stroncek, David F.; Fellowes, Vicki; Pham, Chauha; Khuu, Hanh; Fowler, Daniel H.; Wood, Lauren V.; Sabatino, Marianna (2014-09-17). "Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies". Journal of Translational Medicine. 12 (1): 241. doi: 10.1186/s12967-014-0241-y . ISSN   1479-5876. PMC   4173057 . PMID   25223845.
  27. ↑ Castiello, Luciano; Sabatino, Marianna; Zhao, Yingdong; Tumaini, Barbara; Ren, Jiaqiang; Ping, Jin; Wang, Ena; Wood, Lauren V.; Marincola, Francesco M. (2013-02-01). "Quality Controls in Cellular Immunotherapies: Rapid Assessment of Clinical Grade Dendritic Cells by Gene Expression Profiling". Molecular Therapy. 21 (2): 476–484. doi:10.1038/mt.2012.89. ISSN   1525-0016. PMC   3594020 . PMID   23147403.
  28. ↑ "Leadership | The Children's Inn at NIH". Childrensinn.org. Retrieved 2015-11-17.
  29. ↑ "Association Launches Children's Inn Endowment – The NIH Record -June 13, 2008". Nihrecord.nih.gov. 2008-06-13. Retrieved 2015-11-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.